Author:
Gamboa-Sánchez Concepción,Becerril-Villanueva Enrique,Alvarez-Herrera Samantha,Leyva-Mascareño Gabriela,González-López Sandra L.,Estudillo Enrique,Fernández-Molina Alberto E.,Elizalde-Contreras José Miguel,Ruiz-May Eliel,Segura-Cabrera Aldo,Jiménez-Genchi Janeth,Pavón Lenin,Zamudio Sergio Roberto,Pérez-Sánchez Gilberto
Abstract
Abstract
Background
Major depressive disorder (MDD) affects more than 350 million people worldwide, and there is currently no laboratory test to diagnose it. This pilot study aimed to identify potential biomarkers in peripheral blood mononuclear cells (PBMCs) from MDD patients.
Methods
We used tandem mass tagging coupled to synchronous precursor selection (mass spectrometry) to obtain the differential proteomic profile from a pool of PBMCs from MDD patients and healthy subjects, and quantitative PCR to assess gene expression of differentially expressed proteins (DEPs) of our interest.
Results
We identified 247 proteins, of which 133 had a fold change ≥ 2.0 compared to healthy volunteers. Using pathway enrichment analysis, we found that some processes, such as platelet degranulation, coagulation, and the inflammatory response, are perturbed in MDD patients. The gene-disease association analysis showed that molecular alterations in PBMCs from MDD patients are associated with cerebral ischemia, vascular disease, thrombosis, acute coronary syndrome, and myocardial ischemia, in addition to other conditions such as inflammation and diabetic retinopathy.
Conclusions
We confirmed by qRT-PCR that S100A8 is upregulated in PBMCs from MDD patients and thus could be an emerging biomarker of this disorder. This report lays the groundwork for future studies in a broader and more diverse population and contributes to a deeper characterization of MDD.
Funder
Consejo Nacional de Ciencia y Tecnología
Secretaría de Ciencia, Tecnología e Innovación del Distrito Federal
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Biochemistry
Reference69 articles.
1. Bot M, Chan M, Jansen R, Lamers F, Vogelzangs N, Steiner J, et al. Serum proteomic profiling of major depressive disorder. Transl Psychiatry. 2015;5:e599.
2. Young JJ, Silber T, Bruno D, Galatzer-Levy IR, Pomara N, Marmar CR. Is there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive Disorder. Front Psychiatry. 2016;7:72.
3. Jeffrey M Lyness. Unipolar depression in adults: Assessment and diagnosis - UpToDate. Unipolar depression in adults: Assessment and diagnosis - UpToDate. 2021 [cited 2021 Oct 21]. Available from: https://www.uptodate.com/contents/unipolar-depression-in-adults-assessment-and-diagnosis
4. Mendez-David I, Boursier C, Domergue V, Colle R, Falissard B, Corruble E, et al. Differential Peripheral Proteomic Biosignature of Fluoxetine Response in a Mouse Model of Anxiety/Depression. Front Cell Neurosci. 2017;11:1–16.
5. Xu HB, Zhang RF, Luo D, Zhou Y, Wang Y, Fang L, et al. Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. Int J Neuropsychopharmacol. 2012;15:1413–25.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献